Bortezomib And Low-Dose Dexamethasone With Or Without Continuous Low-Dose Oral Cyclophosphamide For Primary Refractory Or Relapsed Multiple Myeloma: Final Results Of A National Multicenter Randomized Controlled Phase Iii Study
BLOOD(2014)
摘要
Background
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要